Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT03906669
What this trial is testing

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Tumor
St Vincent's Hospital 200
Large-scale testing (Phase 3)Looking for participantsNCT07541079
What this trial is testing

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Who this might be right for
Early Breast Cancer
Genentech, Inc. 300
Early research (Phase 1)Not Yet RecruitingNCT07601620
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 258
Very early researchActive Not RecruitingNCT05333874
What this trial is testing

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Who this might be right for
Breast Cancer, Early-Onset
Rutgers, The State University of New Jersey 34
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Testing effectiveness (Phase 2)Active Not RecruitingNCT06068985
What this trial is testing

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Latin American Cooperative Oncology Group 63
Testing effectiveness (Phase 2)Looking for participantsNCT07407920
What this trial is testing

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2-Positive Breast Carcinoma+1 more
M.D. Anderson Cancer Center 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159
What this trial is testing

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Who this might be right for
Early Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer
Fujian Cancer Hospital 200
Large-scale testing (Phase 3)Not Yet RecruitingNCT07213206
What this trial is testing

CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 1,500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287
What this trial is testing

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Who this might be right for
SHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03735966
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Who this might be right for
HER2 Positive Breast Cancer
Henan Cancer Hospital 75
Not applicableStudy completedNCT07498413
What this trial is testing

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 218,677
Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Not applicableStudy completedNCT04249440
What this trial is testing

Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer

Who this might be right for
Breast CancerHER2Preoperative Systemic Treatment
Zhejiang Cancer Hospital 1,067
Large-scale testing (Phase 3)Study completedNCT02149524
What this trial is testing

Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

Who this might be right for
HER2 Positive Early or Locally Advanced Breast Cancer
Samsung Bioepis Co., Ltd. 875
Testing effectiveness (Phase 2)Looking for participantsNCT07380646
What this trial is testing

The Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer

Who this might be right for
LeucogenRibociclibNeutropenia (Low White Blood Cell Count)+1 more
Second Affiliated Hospital, Zhejiang University, School of Medicine 94
Large-scale testing (Phase 3)Looking for participantsNCT07797218
What this trial is testing

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Shanghai Jiao Tong University School of Medicine 220
Testing effectiveness (Phase 2)Looking for participantsNCT07593976
What this trial is testing

Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer

Who this might be right for
Breast Cancer
Centre Henri Becquerel 42
Early research (Phase 1)Looking for participantsNCT05504707
What this trial is testing

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 30
Testing effectiveness (Phase 2)Study completedNCT02177175
What this trial is testing

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 82
Next Page